Study of CMP-CPS-001 in Healthy Volunteers and Participants With Abnormal Heterozygous OTC Genotype
← catalyst calendarNCT06247670 · readout ≤ 499 d
Sponsored by CAMP4 Therapeutics Corporation (industry) · CAMP — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
120estimated
Sites
2
Countries
Australia, Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-05 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- OTC Deficiency
Interventions
- Drug: CMP-CPS-001
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAdverse events
measured Screening until 42 days (SAD) or 112 days (MAD, OTC) after dosing
Permalink · CAMP's whole pipeline · Catalyst calendar · Every registered study · What changed